«ЭФФЕКТИВНОСТЬ АНАЛОГОВ СОМАТОСТАТИНА (САНДОСТАТИН-ЛАР) В ЛЕЧЕНИИ ГИГАНТСКИХ НЕАКТИВНЫХ АДЕНОМ ГИПОФИЗА»
##article.subject##:
nag, ulkan gipofiv adenoma, qumostatin bilan davolash##article.abstract##
Tadqiqotning maqsadi - qumostatinning samaradorligini o'rganish, u bahaybat azomani davolashda.
Material va tadqiqot usullari. Biz 3X markazlari ma'lumotlarini (RSNIPMC Endokrinologiya markazi, neyroxirurgiya ilmiy markazi, ilmiy markazi, ilmiy markazi ilmiy markazi) shundan iboratki, shunga ko'ra, turli etikalarning gipofiz bezining gipofiz bezining gipenofiy bezi bo'lgan azoomlari o'tkazildi Ularda 3 yil (2015-2017 yillar). (Bularning erkaklari 43, ayollar -25). O'rtacha yosh: erkaklar 37.12 yilni tashkil etdi, ayollar - 38, 15 yil 2 oydan 25 yilgacha cheklovlar.
Tadqiqot usullari quyidagilarni o'z ichiga olgan: 1) umumiy klinik (endokrin, nevrologik holatlar, ko'zning pastki qismlari, ko'zning pastki qismi, ko'zning pastki qismlari uchun) turkchalar, 4 ta turkcha bezlari, 4) ultratovush Ichki va jinsiy a'zolar va boshqalar.) Gormonal qon testlari (StG-1, FSG, Estradiol, progesteron, Cortizol (RIA zarbasi) "Gamma -12" va "Strang 300" metrlari)
Natijalar. Sandostatinni terapiyani olgan 10 nafar bemor gimuitar bezning o'rtacha hajmini barqaror saqlashga ega. 2-guruhda - Saudistatine bo'lmaganda, o'smaning o'sishi tendentsiyasi mavjud (p <0.05)
Xulosa. Operatsiyadan keyingi davrda ulkan nofaol bo'lmagan gipofiz adenomaslari bo'lgan bemorlar o'sish va boshqa bosqinchilikning o'sishining oldini olish uchun, bu jarayonni barqarorlashtirish uchun 3-6-12 oy davomida qumostatinning maqsadini tavsiya qilishlari kerak.
Библиографические ссылки
Borson-Chazot F, Houzard C, Ajzenberg C, et al. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. //Clin Endocrinol (Oxf). 1997;47:589-598.
De Bruin T, Kwekkeboom D, Van’t Verlaat J, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro. // J Clin Endocrinol Metab. 1992;75:1310-1317.
Chen L, White WL, Spetzler RF, Xu B. A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome. //J Neurooncol. 2011;102(1):129–138.
Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. //Eur J Endocrinol. 2006;155(6):823–829.
Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine S; Endocrine Society . Pituitary incidentaloma: an Endocrine Society clinical practice guideline. // J Clin Endocrinol Metab. 2011;96(4):894–904.
Fusco A, Giampietro A, Bianchi A, et al. Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. // Pituitary. 2012;15:571-578.
Hyrcza MD, Ezzat S, Mete O, Asa SL. Pituitary adenomas presenting as sinonasal or nasopharyngeal masses: a case series illustrating potential diagnostic pitfalls. // Am J Surg Pathol. 2017;41(4):525–534
Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA. What is the natural history of nonoperated nonfunctioning pituitary adenomas? // Clin Endocrinol (Oxf). 2007;67(6):938–943.
Korbonits M, Carlsen E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res. 2009;71(Suppl 2):123–130.
4. Mayson SE, Snyder PJ. Silent (clinically nonfunctioning) pituitary adenomas. //J Neurooncol. 2014;117(3):429–436.
Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. // Endocr Pathol. 2015;26(4):349–355.
Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. //Eur J Endocrinol. 2007;156(2):203–216.
.Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptors subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. //Eur J Endocrinol. 2007;156:65-74.
